Table of Contents
Chapter 1. Global HIV Drugs Market Executive Summary
1.1. Global HIV Drugs Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Medication Class
1.3.2. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global HIV Drugs Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer's Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global HIV Drugs Market Dynamics
3.1. Market Drivers
3.1.1. Rise in Demand for HIV Drugs
3.1.2. Increase in Initiatives to Raise Awareness about HIV
3.1.3. Increase in Cases of HIV
3.2. Market Challenges
3.2.1. High Cost of HIV Treatment
3.2.2. Social Stigma and Discrimination
3.3. Market Opportunities
3.3.1. Rise in R&D in Drug Discovery
3.3.2. Increase in Awareness about HIV
3.3.3. Rise in Funding for HIV Awareness and Treatment
Chapter 4. Global HIV Drugs Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model
4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global HIV Drugs Market Size & Forecasts by Medication Class 2022-2032
5.1. Segment Dashboard
5.2. Global HIV Drugs Market: Medication Class Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Multi-Class Combination Drugs
5.2.2. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
5.2.3. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
5.2.4. Protease Inhibitors (PIs)
5.2.5. Entry Inhibitors
5.2.6. HIV Integrase Strand Transfer Inhibitors
5.2.7. Others
Chapter 6. Global HIV Drugs Market Size & Forecasts by Distribution Channel 2022-2032
6.1. Segment Dashboard
6.2. Global HIV Drugs Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Hospital Pharmacies
6.2.2. Drug Stores and Retail Pharmacies
6.2.3. Online Pharmacies
Chapter 7. Global HIV Drugs Market Size & Forecasts by Region 2022-2032
7.1. North America HIV Drugs Market
7.1.1. U.S. HIV Drugs Market
7.1.1.1. Medication Class breakdown size & forecasts, 2022-2032
7.1.1.2. Distribution Channel breakdown size & forecasts, 2022-2032
7.1.2. Canada HIV Drugs Market
7.2. Europe HIV Drugs Market
7.2.1. U.K. HIV Drugs Market
7.2.2. Germany HIV Drugs Market
7.2.3. France HIV Drugs Market
7.2.4. Spain HIV Drugs Market
7.2.5. Italy HIV Drugs Market
7.2.6. Rest of Europe HIV Drugs Market
7.3. Asia-Pacific HIV Drugs Market
7.3.1. China HIV Drugs Market
7.3.2. India HIV Drugs Market
7.3.3. Japan HIV Drugs Market
7.3.4. Australia HIV Drugs Market
7.3.5. South Korea HIV Drugs Market
7.3.6. Rest of Asia Pacific HIV Drugs Market
7.4. Latin America HIV Drugs Market
7.4.1. Brazil HIV Drugs Market
7.4.2. Mexico HIV Drugs Market
7.4.3. Rest of Latin America HIV Drugs Market
7.5. Middle East & Africa HIV Drugs Market
7.5.1. Saudi Arabia HIV Drugs Market
7.5.2. South Africa HIV Drugs Market
7.5.3. Rest of Middle East & Africa HIV Drugs Market
Chapter 8. Competitive Intelligence
8.1. Key Company SWOT Analysis
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. GlaxoSmithKline plc
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Market Strategies
8.3.2. Johnson & Johnson
8.3.3. Gilead Sciences, Inc.
8.3.4. F. Hoffmann-La Roche Ltd.
8.3.5. Cipla Ltd.
8.3.6. Merck & Co., Inc.
8.3.7. Bristol-Myers Squibb Company
8.3.8. AbbVie Inc.
8.3.9. Boehringer Ingelheim International GmbH
8.3.10. Teva Pharmaceutical Industries Ltd.
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes